CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Anti-SARS-CoV2 SerologyWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug363 Dexamethasone Wiki 0.71
drug923 Questionnaire Wiki 0.33

Correlated MeSH Terms (6)

Name (Synonyms) Correlation
D011024 Pneumonia, Viral NIH 0.14
D055371 Acute Lung Injury NIH 0.13
D012127 Respiratory Distress Syndrome, Newborn NIH 0.13
D012128 Respiratory Distress Syndrome, Adult NIH 0.11
D045169 Severe Acute Respiratory Syndrome NIH 0.06
D018352 Coronavirus Infections NIH 0.05

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff

Emerging in China in December 2019, Covid-19, whose pathogen is SARS-Cov-2, was declared a global pandemic in March 2020. The clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress and even death. Transmission occurs through droplets, with a R0 of approximately 3. Rapidly, population protection measures were put in place by governments, including the confinement of all persons whose functions were not considered essential and the closure of educational institutions. Health care institutions are places at risk of Covid-19 transmission and hospital staff are particularly exposed, either through direct contact with patients, contact with exposed persons or through the environment. In order to protect personnel, hygiene measures were immediately recalled and reinforced. This study is aimed at evaluating the incidence rate of anti-SARS-Cov2 seroconversion over 2 months among hospital staff, without any supposed anti-Covid treatment 19.

NCT04387838 Sars-CoV2 Diagnostic Test: Anti-SARS-CoV2 Serology Other: Questionnaire

Primary Outcomes

Description: Change of Anti-SARS-Cov2 serological status between Day 0 and Day 60, measured in blood sample.

Measure: Anti-SARS-Cov2 seroconversion between Day 0 and Day 60.

Time: From Day 0 to Day 60

Description: Change of Anti-SARS-Cov2 serological status between Day 0 and Day 30, measured in blood sample.

Measure: Anti-SARS-Cov2 seroconversion between Day 0 and Day 30.

Time: From Day 0 to Day 30

Description: Change of Anti-SARS-Cov2 serological status between Day 30 and Day 60, measured in blood sample.

Measure: Anti-SARS-Cov2 seroconversion between Day 30 and Day 60.

Time: From Day 30 to Day 60

Secondary Outcomes

Description: Anti-SARS-Cov2 seroprevalence measured in blood sample collected at Day 0.

Measure: Anti-SARS-Cov2 seroprevalence at Day 0.

Time: Day 0

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and sex

Measure: Correlation between seroconversion and socio-demographic factors - sex

Time: Day 60

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and age

Measure: Correlation between seroconversion and socio-demographic factors - age

Time: Day 60

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and job type (nurse, physician, etc.)

Measure: Correlation between seroconversion and professional factors - job type

Time: Day 60

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and personal protective equipment type

Measure: Correlation between seroconversion and professional factors - personal protective equipment type

Time: Day 60

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and contact with infected individuals

Measure: Correlation between seroconversion and non-professional factors - contact with infected individuals

Time: Day 60

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and wearing of professional equipment

Measure: Correlation between seroconversion and non-professional factors - wearing of professional equipment

Time: Day 60

Description: Correlation between seroconversion (measured in blood sample) at Day 60 and respect of barrier gestures

Measure: Correlation between seroconversion and non-professional factors - respect of barrier gestures

Time: Day 60

No related HPO nodes (Using clinical trials)